BR0116686A - Silenced anti-cd28 Antibodies and usage - Google Patents

Silenced anti-cd28 Antibodies and usage

Info

Publication number
BR0116686A
BR0116686A BR0116686-7A BR0116686A BR0116686A BR 0116686 A BR0116686 A BR 0116686A BR 0116686 A BR0116686 A BR 0116686A BR 0116686 A BR0116686 A BR 0116686A
Authority
BR
Brazil
Prior art keywords
antibodies
usage
silenced
silenced anti
methods
Prior art date
Application number
BR0116686-7A
Other languages
Portuguese (pt)
Inventor
J Yun Tso
Paul Hinton
Maximiliano Vasquez
Kouichi Tamura
Yasuyuki Higashi
Nobuo Seki
Hirotsugu Ueda
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR0116686A publication Critical patent/BR0116686A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"ANTICORPOS ANTI-CD28 SILENCIADOS E USO DOS MESMOS". A presente invenção provê anticorpos anti-CD28 deficientes em atividade mitogênica (anticorpos anti-CD28 silenciados), métodos para sua produção, composições contendo o anticorpo e métodos de imunossupressão, para induzir tolerância à célula T e para tratar rejeições de transplante de órgão e/ou tecido."Silenced Anti-CD28 Antibodies and USE". The present invention provides mitogenic activity-deficient anti-CD28 antibodies (silenced anti-CD28 antibodies), methods for their production, antibody-containing compositions and immunosuppression methods, to induce T cell tolerance and to treat organ transplant rejections and / or fabric.

BR0116686-7A 2000-12-14 2001-12-14 Silenced anti-cd28 Antibodies and usage BR0116686A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (1)

Publication Number Publication Date
BR0116686A true BR0116686A (en) 2003-12-30

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116686-7A BR0116686A (en) 2000-12-14 2001-12-14 Silenced anti-cd28 Antibodies and usage

Country Status (18)

Country Link
EP (1) EP1341553A4 (en)
JP (1) JP2004515243A (en)
KR (1) KR20040020866A (en)
CN (1) CN1272345C (en)
AR (1) AR031924A1 (en)
AU (2) AU2002226086C1 (en)
BR (1) BR0116686A (en)
CA (1) CA2432736A1 (en)
CZ (1) CZ20031909A3 (en)
HU (1) HUP0400697A3 (en)
IL (1) IL156262A0 (en)
MX (1) MXPA03005327A (en)
NO (1) NO20032542L (en)
NZ (1) NZ526569A (en)
PL (1) PL363239A1 (en)
RU (1) RU2261723C2 (en)
WO (1) WO2002047721A1 (en)
ZA (1) ZA200305384B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
FR2951176A1 (en) 2009-10-09 2011-04-15 Tcl Pharma MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR
EP2536764B1 (en) * 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
JP6884858B2 (en) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド Pharmaceutical product and its manufacturing method
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN113692286A (en) * 2019-03-14 2021-11-23 比昂生物制剂公司 A method for immunosuppression
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc Anti-cd28 compositions
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521288A (en) * 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein

Also Published As

Publication number Publication date
EP1341553A4 (en) 2004-07-28
JP2004515243A (en) 2004-05-27
AU2002226086C1 (en) 2006-03-09
RU2261723C2 (en) 2005-10-10
AU2002226086B2 (en) 2005-08-25
AR031924A1 (en) 2003-10-08
RU2003121231A (en) 2005-02-10
CZ20031909A3 (en) 2003-11-12
NZ526569A (en) 2005-07-29
NO20032542L (en) 2003-08-07
KR20040020866A (en) 2004-03-09
PL363239A1 (en) 2004-11-15
CA2432736A1 (en) 2002-06-20
WO2002047721A1 (en) 2002-06-20
HUP0400697A2 (en) 2004-06-28
ZA200305384B (en) 2004-10-11
MXPA03005327A (en) 2004-12-03
IL156262A0 (en) 2004-01-04
HUP0400697A3 (en) 2007-05-02
CN1489473A (en) 2004-04-14
AU2608602A (en) 2002-06-24
NO20032542D0 (en) 2003-06-05
EP1341553A1 (en) 2003-09-10
CN1272345C (en) 2006-08-30

Similar Documents

Publication Publication Date Title
BR0116686A (en) Silenced anti-cd28 Antibodies and usage
ATE412432T1 (en) INTERNALIZING ERBB2 ANTIBODIES
DE69129302D1 (en) TUMOR GROWTH INHIBITORS FROM FABRICS, METHODS OF THEIR PRODUCTION AND USE
ES2293973T3 (en) ANTIBODIES ANTI-CCR2 HUMANIZED AND METHODS OF USE OF THE SAME.
CR10878A (en) ANTIBODIES FOR CD40 (EXP. 7343 DIVISIONAL)
RS80704A (en) ANTI- av?6.ANTIBODIES
PT1315520E (en) USE OF BIASPECIFIC AND TRIESPECIFIC TRIFUNCTIONAL ANTIBODIES FOR THE TREATMENT OF MALIGNANT ASCITES
BRPI0410031A (en) optimized fc variants and methods for their generation
BR9606706A (en) Bispecific or bivalent antibody fragment analog use process to produce the same
DE60226797D1 (en) Instrument for introducing fasteners for transplants
DE69619493T2 (en) POLYPEPTIDE-DENDRIMER COMPLEXES
IL195338A (en) Antibody comprising an fc variant comprising d or e amino acid substitution at position 239 and pharmaceutical composition and use thereof
ATE248605T1 (en) CROSS-REACTIVE MONOCLONAL ANTIBODIES SPECIFIC FOR E-SELECTIN AND P-SELECTIN
DE69433406D1 (en) ANTIBODIES AGAINST CD40
RS53984B1 (en) Ip-10 antibodies and their uses
DK0973550T3 (en) Antagonistic anti-AVB3 integrin antibodies
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
BR0210965A (en) Chelator conjugate, radiometal complex, radiopharmaceutical, kit for preparing same, compound, and process for preparing same
ATE395364T1 (en) ANTIBODIES DIRECTED AGAINST PROCALCITONIN, THEIR PRODUCTION AND USE
DE69837387D1 (en) (d) METHADONE, A NON-OPIOID PAIN
DK1068328T3 (en) Treatment and diagnosis of staphylococcal infections
BR0314716A (en) Lfa-1 alpha subunit antibodies and methods of use
BR0109164A (en) Monoclonal antibodies to the human LDL receptor, production and use thereof
DE69814007D1 (en) Magnetic fastener, especially for clothing
ATE202117T1 (en) ANGIOTENSIN II RECEPTOR TYPE I SPECIFIC MONOCLONAL ANTIBODIES AND HYBRIDOMA

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO. LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.